Global & Disaster Medicine

Archive for the ‘AMR-Antimicrobial Resistance’ Category

Malawi: “…In Klebsiella….resistance rose from 12% in 2003 to more than 90% in 2016. In E. coli, resistance rose from 1% to 30% in the same time period….”


“Malawi is one of the poorest countries in the world, ranking 170th out of 188 on the United Nations’ human development index. More than 70% of its 18 million people survive on less than $1.90 a day, the international benchmark of poverty.

Most Malawians do not own televisions, cars or phones or have internet. In rural areas, people grow their own food.
And now, the country is facing an epidemic of infections causing sepsis, one of the leading causes of death among newborns. It killed nearly 20% of them in 2016; by comparison, in the UK, sepsis is responsible for less than 2% of infant deaths.
A combination of factors, all related to poverty, mean the percentage of babies dying of sepsis has barely fallen since 2000 despite improvements in the health care system…..”

WHO’s first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in both high- and low-income countries.


High levels of antibiotic resistance found worldwide, new data shows

News release

WHO’s first release of surveillance data on antibiotic resistance reveals high levels of resistance to a number of serious bacterial infections in both high- and low-income countries.

WHO’s new Global Antimicrobial Surveillance System (GLASS) reveals widespread occurrence of antibiotic resistance among 500 000 people with suspected bacterial infections across 22 countries.

The most commonly reported resistant bacteria were Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, followed by Salmonella spp. The system does not include data on resistance of Mycobacterium tuberculosis, which causes tuberculosis (TB), as WHO has been tracking it since 1994 and providing annual updates in the Global tuberculosis report.

Among patients with suspected bloodstream infection, the proportion that had bacteria resistant to at least one of the most commonly used antibiotics ranged tremendously between different countries – from zero to 82%. Resistance to penicillin – the medicine used for decades worldwide to treat pneumonia – ranged from zero to 51% among reporting countries. And between 8% to 65% of E. coli associated with urinary tract infections presented resistance to ciprofloxacin, an antibiotic commonly used to treat this condition.

“The report confirms the serious situation of antibiotic resistance worldwide,” says Dr Marc Sprenger, director of WHO’s Antimicrobial Resistance Secretariat.

“Some of the world’s most common – and potentially most dangerous – infections are proving drug-resistant,” adds Sprenger. “And most worrying of all, pathogens don’t respect national borders. That’s why WHO is encouraging all countries to set up good surveillance systems for detecting drug resistance that can provide data to this global system.”

To date, 52 countries (25 high-income, 20 middle-income and 7 low-income countries) are enrolled in WHO’s Global Antimicrobial Surveillance System. For the first report, 40 countries provided information about their national surveillance systems and 22 countries also provided data on levels of antibiotic resistance.

“The report is a vital first step towards improving our understanding of the extent of antimicrobial resistance. Surveillance is in its infancy, but it is vital to develop it if we are to anticipate and tackle one of the biggest threats to global public health,” says Dr Carmem Pessoa-Silva, who coordinates the new surveillance system at WHO.

Data presented in this first GLASS report vary widely in quality and completeness. Some countries face major challenges in building their national surveillance systems, including a lack of personnel, funds and infrastructure.

However, WHO is supporting more countries to set up national antimicrobial resistance surveillance systems that can produce reliable, meaningful data. GLASS is helping to standardize the way that countries collect data and enable a more complete picture about antimicrobial resistance patterns and trends.

Solid drug resistance surveillance programmes in TB, HIV and malaria have been functioning for many years and have helped estimate disease burden, plan diagnostic and treatment services, monitor the effectiveness of control interventions, and design effective treatment regimens to address and prevent future resistance. GLASS is expected to perform a similar function for common bacterial pathogens.

The rollout of GLASS is already making a difference in many countries. For example, Kenya has enhanced the development of its national antimicrobial resistance system; Tunisia started to aggregate data on antimicrobial resistance at national level; the Republic of Korea completely revised its national surveillance system to align with the GLASS methodology, providing data of very high quality and completeness; and countries such as Afghanistan or Cambodia that face major structural challenges have enrolled in the system and are using the GLASS framework as an opportunity for strengthening their AMR surveillance capacities. In general, national participation in GLASS is seen as a sign of growing political commitment to support global efforts to control antimicrobial resistance.

Note to editors

The need for a global surveillance system was highlighted by WHO in 2014 in the Antimicrobial resistance global report on surveillance.

In October 2015, WHO launched the Global Antimicrobial Surveillance System (GLASS) working closely with WHO Collaborating Centres and existing antimicrobial resistance surveillance networks and based on the experience of other WHO surveillance programmes. For example, TB drug resistance surveillance has been implemented in 188 countries over the past 24 years. HIV drug resistance surveillance started in 2005 and by 2017, over 50 countries had reported data on pretreatment and acquired resistance using standardized survey methods.

Any country, at any stage of the development of its national antimicrobial resistance surveillance system, can enrol in GLASS. Countries are encouraged to implement the surveillance standards and indicators gradually, based on their national priorities and available resources.

GLASS will eventually incorporate information from other surveillance systems related to antimicrobial resistance in humans, such as in the food chain, monitoring of antimicrobial consumption, targeted surveillance projects, and other related data.

All data produced by GLASS is available free online and will be updated regularly.

Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General, has underscored his aim to make antimicrobial resistance one of WHO’s top priorities by bringing together experts working on this issue under a newly created strategic initiatives cluster.

Media contact:

Christian Lindmeier
Telephone: +41 22 791 1948
Mobile: +41 79 500 6552

Antimicrobial Resistance (AMR): Another type of pandemic? “We still face two trends that spell potential disaster: new classes of drugs are not being invented and resistance to existing drugs continues to spread inexorably.”

World Economic Forum

“…..The risks posed by AMR have continued to intensify in the five years since the 2013 report. Numerous welcome initiatives have been launched, but concrete successes in addressing the two drivers identified above remain elusive. We still face two trends that spell potential disaster: new classes of drugs are not being invented and resistance to existing drugs continues to spread inexorably. The stakes are incredibly high—if resistance overtakes all our available antibiotics, it would spell the “the end of modern medicine”.…..”

The Pharmaceutical Journal. 2017. “Chief Medical Officer Warns Antibiotic Resistance Could Signal ‘End of Modern Medicine’”. The Pharmaceutical Journal. 17 October 2017.

Selected AMR Rates 

Resistance of Staphylococcus aureus to Oxadcillin (MRSA), % Resistant (invasive isolates)

Resistance of Klebsiella pneumoniae to Cephalosporins (3rd gen), % Resistant (invasive isolates)

Source: Figure courtesy Center for Disease Dynamics, Economics and Policy. Used with permission via Creative Commons license.
Note: Countries in white indicate no data available.



Recent Posts